Lupin Outlook for the Week (Feb 26, 2018 – Mar 02, 2018)
EquityPandit’s Outlook for Lupin for the week (Feb 26, 2018 – Mar 02, 2018) : LUPIN: Lupin closed the week on negative note losing around 2.20%....
Tag : Lupin
Lupin gets approval from USFDA to market generic Tamiflu
Lupin has received final approval from the US health regulator, for its Oseltamivir Phosphate. In a BSE filing the company stated that, it has received final...
Lupin Outlook for the Week (Feb 19, 2018 – Feb 23, 2018)
EquityPandit’s Outlook for Lupin for the week (Feb 19, 2018 – Feb 23, 2018) : LUPIN: Lupin closed the week on positive note gaining around 0.40%....
Lupin introduces generic influenza treatment capsules in US
Lupin has launched generic Oseltamivir Phosphate capsules, in the US market which is used fro treating influenza. In a BSE filing the company stated that, it...
Lupin Outlook for the Week (Feb 12, 2018 – Feb 16, 2018)
EquityPandit’s Outlook for Lupin for the week (Feb 12, 2018 – Feb 16, 2018) : LUPIN: Lupin closed the week on negative note losing around 3.00%....
Lupin Q3 profit falls 65% YoY to Rs.222 crore
Lupin has reported a fall of 65% YoY in its consolidated profit to Rs.221.7 crore, mainly due to continued pricing pressure in the US and...
Lupin Outlook for the Week (Feb 05, 2018 – Feb 09, 2018)
EquityPandit’s Outlook for Lupin for the week (Feb 05, 2018 – Feb 09, 2018) : LUPIN: Lupin closed the week on negative note losing around 10.80%....
Lupin Outlook for the Week (Jan 29, 2018 – Feb 02, 2018)
EquityPandit’s Outlook for Lupin for the week (Jan 29, 2018 – Feb 02, 2018) : LUPIN: Lupin closed the week on positive note gaining around 4.10%....
Lupin Outlook for the Week (Jan 22, 2018 – Jan 25, 2018)
EquityPandit’s Outlook for Lupin for the week (Jan 22, 2018 – Jan 25, 2018) : LUPIN: Lupin closed the week on positive note gaining around 0.50%....
Lupin forays into over-the-counter segment
Lupin has forayed into over-the-counter (OTC) segment in the country and plans to achieve Rs.300 crore turnover in the vertical in the next 5 years....